Co-Authors
This is a "connection" page, showing publications co-authored by Benjamin Derman and Andrzej Jakubowiak.
Connection Strength
11.332
-
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant. Hemasphere. 2025 Aug; 9(8):e70186.
Score: 0.923
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.869
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.848
-
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
Score: 0.811
-
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
Score: 0.775
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.751
-
Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.
Score: 0.700
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
Score: 0.674
-
Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
Score: 0.643
-
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol. 2026 Apr; 13(4):e241-e253.
Score: 0.240
-
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 Jul 22; 9(14):3613-3616.
Score: 0.229
-
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma. Hemasphere. 2025 Jul; 9(7):e70178.
Score: 0.229
-
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Blood Neoplasia. 2025 Nov; 2(4):100124.
Score: 0.227
-
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
Score: 0.224
-
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
Score: 0.218
-
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 09 06; 29(9):806-810.
Score: 0.216
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
Score: 0.216
-
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.
Score: 0.202
-
Measurable residual disease in peripheral blood in myeloma: dream or reality. Curr Opin Oncol. 2023 Nov 01; 35(6):574-580.
Score: 0.201
-
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.
Score: 0.186
-
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
Score: 0.186
-
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
Score: 0.166
-
Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.
Score: 0.166
-
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
Score: 0.166
-
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
Score: 0.163
-
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
Score: 0.156
-
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
Score: 0.155
-
Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precis Oncol. 2026 Jul; 10(7):e2501121.
Score: 0.061
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
Score: 0.061
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.
Score: 0.060
-
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025 Sep; 39(9):2285-2288.
Score: 0.057
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
Score: 0.056
-
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma. Blood Neoplasia. 2025 Feb; 2(1):100065.
Score: 0.055
-
Germline predisposition in multiple myeloma. iScience. 2025 Jan 17; 28(1):111620.
Score: 0.055
-
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
Score: 0.054
-
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
Score: 0.053
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
Score: 0.050
-
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
Score: 0.048
-
Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Cancers (Basel). 2022 Oct 29; 14(21).
Score: 0.047
-
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106.
Score: 0.047
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.046
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
Score: 0.041